Antimicrobial susceptibility patterns of clinical Escherichia coli isolates from dogs and cats in the United States: January 2008 through January 2013

Veterinary Microbiology

Volumn 179, Issue 3-4, 2015, Pages 287-295

  Thungrat, Kamoltip ^a   Price, Stuart B ^a   Carpenter, D Mark ^a   Boothe, Dawn Merton ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Antimicrobials; E. coli; Infections; Resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFALOTIN; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ENROFLOXACIN; GENTAMICIN; MEROPENEM; TIMENTIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CAT; CONTROLLED STUDY; DOG; ESCHERICHIA COLI; FEMALE; MALE; MIC50; MIC75; MIC90; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; UNITED STATES; ANIMAL; CAT DISEASES; DOG DISEASES; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; VETERINARY;

BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; ESCHERICHIA COLI;

ANIMALS; ANTI-BACTERIAL AGENTS; CAT DISEASES; CATS; DOG DISEASES; DOGS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 84938740163     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2015.06.012     Document Type: Article

References (35)

1. Aly S.A., Debevalya N., Suh S.J., Oryazabal O.A., Boothe D.M. Molecular mechanisms of antimicrobial resistance in fecal E. coli of healthy dogs after enrofloxacin or amoxicillin administration. Can. J. Microbiol. 2012, 58:1288-1294.
2. Anderson A.D., Nelson J.M., Rossiter S., Angulo F.J. Public health consequences of use of antimicrobial agents in food animals in the United States. Microb. Drug Resist. 2003, 9:373-379.
3. Bailey T.C., Little J.R., Littenberg B., Reichley R.M., Dunagan W.C. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis. 1997, 24:786-795.
4. Baquero F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug. Resist. Upadates 2001, 4:93-105.
5. Boerlin P., White D.G. Antimicrobial resistance and its epidemiology. Antimicrobial Therapy in Veterinary Medicine 2013, 21-40. John Wiley & Sons, Oxford. 5th ed. S. Giguère, J.F. Prescott, P.M. Dowling (Eds.).
6. Boothe D.M., Boeckh A., Simpson R.B., Dubose K. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J. Vet. Intern. Med. 2006, 20:1297-1306.
7. Clinical and Laboratory Standards Institute (CLSI), 2010. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA, USA. ISBN 1-56238- 716-2.
8. Clinical and Laboratory Standards Institute (CLSI), 2013. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacterial Isolated from Animals; Approved Standard. Fourth Edition and Supplement, CLSI document VET01-A4 (standard) and VET01-S2 (supplement). Clinical and Laboratory Standards Institute, Wayne PA. USA. ISBN 1-56238- 8770.
9. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin. Infect. Dis. 2006, 42:S82-S89.
10. Coyne K.S., Sexton C.C., Thompson C.L., Milsom I., Irwin D., Kopp Z.S., Chapple C.R., Kaplan S., Tubaro A., Aiyer L.P., Wein A.J. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009, 104:352-360.
11. Elkin E. Beyond binary outcomes: PROC LOGISTIC to model ordinal and nominal dependent variables. SAS Conference Proceedings: Western Users of SAS Software 2004, 1-8.
12. ® User's Group International Conference 2006, Paper 204-231.
13. Féria C., Ferreira E., Correia J.D., Gonçalves J., Caniça M. Patterns and mechanisms of resistance to β-lactams and β-lactamase inhibitors in uropathogenic E. coli isolated from dogs in Portugal. J. Antimicrob. Chemother. 2002, 49:77-85.
14. Hosmer D.W., Lemeshow S., Sturdivant R.X. Model-building strategies and methods for logistic regression. Applied Logistic Regression 2013, 89-151. John Wiley & Sons, New Jersey. 3rd ed.
15. Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Pankuch G.A., Appelbaum P.C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob. Agents Chemother. 1999, 43:1901-1908.
16. Karlowsky J.A., Hoban D.J., DeCorby M.R., Laing N.M., Zhanel G.G. Fluoroquinolone- resistant urinary isolates of E. coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob. Agents. Chemother. 2006, 50:2251-2254.
17. Killgore K.M., March K.L., Guglielmo B.J. Risk factors for community-acquired ciprofloxacin-resistant E. coli urinary tract infection. Ann. Pharmacother. 2004, 38:1148-1152.
18. Liang K.Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
19. Liu X., Boothe D.M., Thungrat K., Aly S. Mechanisms accounting for fluoroquinolone multidrug resistance E. coli isolated from companion animals. Vet. Microbiol. 2012, 161:159-168.
20. Liu X., Boothe D.M., Jin Y., Thungrat K. In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline E. coli uropathogens in the United States. World J. Microbiol. Biotechnol. 2013, 29:347-354.
21. Magiorakos A.-P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., Paterson D.L., Rice L.B., Stelling J., Struelens M.J., Vatopoulos A., Weber J.T., Monnet D.L. Multidrug- resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18:268-281.
22. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
23. Mateus A., Brodbelt D.C., Barber N., Stärk K.D. Antimicrobial usage in dogs and cats in first opinion veterinary practices in the UK. J. Small Anim. Pract. 2011, 52:515-521.
24. Miller K., O'Neill A.J., Chopra I. E. coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections. Antimicrob. Agents Chemother. 2004, 48:23-29.
25. Morris D.O., Rook K.A., Shofer F.S., Rankin S.C. Screening of Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi isolates obtained from small companion animals for antimicrobial resistance: a retrospective review of 749 isolates (2003-04). Vet. Dermatol. 2006, 17:332-337.
26. Murphy C., Reid-Smith R.J., Prescott J.F., Bonnett B.N., Poppe C., Boerlin P., Weese J.S., Janecko N., McEwen S.A. Occurrence of antimicrobial resistant bacteria in healthy dogs and cats presented to private veterinary hospitals in southern Ontario: a preliminary study. Can. Vet. J. 2009, 50:1047-1053.
27. NORM/NORM-VET, 2012. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø / Oslo 2013. ISSN. 1502-2307 (print) / 1890-9965 (electronic).
28. Paul M., Shani V., Muchtar E., Kariv G., Robenshtok E., Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob. Agents. Chemother. 2010, 54:4851-4863.
29. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J. Antimicrob. Chemother. 2007, 60:1018-1029.
30. Sanchez G.V., Adams S.J., Baird A.M., Master R.N., Clark R.B., Bordon J.M. E. coli antimicrobial resistance increased faster among geriatric outpatients compared with adult outpatients in the USA, 2000-10. J. Antimicrob. Chemother. 2000, 68:1838-1841.
31. Shaheen B.W., Boothe D.M., Oyarzabal O.A., Smaha T. Antimicrobial resistance profiles and clonal relatedness of canine and feline E. coli pathogens expressing multidrug resistance in the United States. J. Vet. Intern. Med. 2010, 24:323-330.
32. SVARM, 2011. Swedish Veterinary Antimicrobial Resistance Monitoring. The National Veterinary Institute (SVA), Uppsala, Sweden, 2012. Available at: , ISSN 1650-6332. http://www.sva.se.
33. Trepanier L.A., Danhof R., Toll J., Watrous D. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J. Vet. Intern. Med. 2003, 17:647-652.
34. Weese, J.S., Blondeau, J.M., Boothe, D., Breitschwerdt, E.B., Guardabassi, L., Hillier, A., Lloyd, D.H., Papich, M.G., Rankin, S.C., Turnidge, J.D., Sykes, J.E., 2011. Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. Vet. Med. Int. Article ID 263,768. http://dx.doi.org/10.4061/2011/263768.
35. Winokur P.L., Vonstein D.L., Hoffman L.J., Uhlenhopp E.K., Doern G.V. Evidence for transfer of CMY-2 AmpC β-lactamase plasmids between E. coli and Salmonella isolates from food animals and humans. Antimicrob. Agents Chemother 2001, 45:2716-2722.